D. E. Shaw & Co., Inc. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAB5. A total of 11 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$32,805,000
+8.5%
17,444,0000.0%0.04%
+35.7%
Q1 2022$30,242,000
-0.5%
17,444,0000.0%0.03%
+12.0%
Q4 2021$30,383,000
+153.4%
17,444,000
+158.8%
0.02%
+127.3%
Q3 2021$11,988,000
+53.2%
6,741,000
+68.5%
0.01%
+57.1%
Q2 2021$7,824,0004,000,0000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
WOLVERINE ASSET MANAGEMENT LLC 33,153,000$58,989,0000.51%
TENOR CAPITAL MANAGEMENT Co., L.P. 11,250,000$20,091,0000.46%
SSI INVESTMENT MANAGEMENT LLC 3,573,000$6,351,0000.38%
LINDEN ADVISORS LP 10,703,000$19,063,0000.11%
Calamos Advisors LLC 10,000,000$17,822,0000.08%
PALISADE CAPITAL MANAGEMENT, LP 2,000,000$3,557,0000.08%
Hudson Bay Capital Management LP 2,000,000$3,562,0000.05%
D. E. Shaw & Co., Inc. 6,741,000$11,988,0000.01%
BNP PARIBAS FINANCIAL MARKETS 3,294,000$5,870,620,0000.01%
FIRST HAWAIIAN BANK 75,000$133,0000.01%
View complete list of HALOZYME THERAPEUTICS INC shareholders